Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ-0,39
KB676676,50,90
PKN65,3865,62,05
Msft-1,89
Nokia4,70054,848-2,57
IBM-0,85
Mercedes-Benz Group AG64,4764,490,27
PFE-0,35
05.12.2022 22:01:42
Indexy online
AD Index online
select
AD Index online
 

  • 05.12.2022 17:35:16
Hikma Pharma (HIK.L, London)
Poslední obchod Změna (%) Změna (GBP) Objem obchodů (GBP)
15,14 -1,01 -0,16 6 526 986
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 05.12.2022
Popis společnosti
Obecné informace
Název společnostiHikma Pharmaceuticals Plc
TickerHIK
Kmenové akcie:Ordinary Shares
RICHIK.L
ISINGB00B0LCW083
Poslední známé roční výsledky31.12.2021
Poslední známé čtvrtletní výsledky30.06.2022
Počet zaměstnanců k 31.12.2021 8 703
Akcie v oběhu k 30.11.2022 220 229 953
MěnaUSD
Kontaktní informace
Ulice1 New Burlington Place
MěstoLONDON
PSČW1S 2HR
ZeměUnited Kingdom
Kontatní osoba 
Funkce kontaktní osoby 
Telefon442 073 992 760
Fax442073992761

Business Summary: Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing, marketing and selling of a broad range of generic, branded and in-licensed pharmaceuticals products in solid, semi-solid, liquid and injectable final dosage forms. The Company operates through three segments, such as Injectables, Generics and Branded. The Injectables business develops and manufactures generic injectable products, which are primarily used in hospitals. The Generics business develops and manufactures oral and other non-injectable generic products. The Branded business develops and manufactures branded generics and markets and sells in-licensed patented products in Middle East/North Africa (MENA). The Company’s products are sold in the retail and hospital markets. It also markets its products in Canada, which includes approximately 25 sterile injectable products, three in-licenced ophthalmic products and a pipeline of seven additional products.
Financial Summary: BRIEF: For the six months ended 30 June 2022, Hikma Pharmaceuticals Plc revenues decreased less than 1% to $1.21B. Net income decreased 30% to $173M. Revenues reflect Injectable Pharmaceuticals segment increase of 9% to $538M, Branded Pharmaceuticals segment increase of 6% to $339M, Others segment increase of 20% to $6M, Middle East and North Africa segment increase of 5% to $414M.
Odvětvová klasifikace
TRBC2012Pharmaceuticals (NEC)
RBSS2004Pharmaceuticals - Generic & Specialty
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSPharmaceutical Preparation Manufacturing
NAICSDrugs and Druggists' Sundries Merchant Wholesalers
NAICS2007Pharmaceutical Preparation Mfg
NAICS2007Drugs and Druggists' Sundries Merchant Wholesalers
NAICS1997Pharmaceutical Preparation Manufacturing
NAICS1997Drug, Drug Proprietaries and Druggists' Sundries Wholesalers
SICPharmaceutical Preparations
SICDrugs/proprietaries/sundries



  • Poslední aktualizace: 05.12.2022
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Executive Chairman of the BoardSaid Darwazah6420.02.201801.07.2007
Executive Vice Chairman of the Board, President of MENAMazen Darwazah6308.09.2005
Chief Financial OfficerKhalid Nabilsi-01.01.2008
President, US Generics DivisionBrian Hoffman-01.01.2015
President - InjectablesRiad Mishlawi-01.01.2011
Executive Vice President - Corporate Development and M&ABassam Wael Rushdi Kanaan57
Executive Vice President - Organisational DevelopmentMajda Labadi-
Executive Vice President - Business OperationsHenriette Nielsen-01.01.2018
Executive Vice President - Strategic Planning and Global AffairsSusan Ringdal-
Chief Scientific OfficerShahin Fesharaki-01.01.2019